Carbidopa

Generic Name
Carbidopa
Brand Names
Dhivy, Duodopa, Duopa, Lodosyn, Parcopa, Rytary, Sinemet, Stalevo
Drug Type
Small Molecule
Chemical Formula
C10H14N2O4
CAS Number
28860-95-9
Unique Ingredient Identifier
KR87B45RGH
Background

Carbidopa presents a chemical denomination of N-amino-alpha-methyl-3-hydroxy-L-tyrosine monohydrate. It potently inhibits aromatic amino acid decarboxylase (DDC) and due to its chemical properties, it does not cross the blood-brain barrier. Due to its activity, carbidopa is always administered concomitantly with levodopa. An individual formulation containing...

Indication

Carbidopa is indicated with levodopa for the treatment of symptoms of idiopathic Parkinson disease, postencephalitic parkinsonism and symptomatic parkinsonism followed by carbon monoxide or manganese intoxication.

The combination therapy is administered for the reduction of levodopa-driven nausea and vomiting.
...

Associated Conditions
Parkinson's Disease (PD), Parkinsonism post encephalitic, Symptomatic Parkinson Disease, Levodopa-driven nausea and vomiting
Associated Therapies
-
Clinical Trials
Related News
investing.com
·

Amneal Pharmaceuticals' SWOT analysis: generic drug maker's stock poised for growth

Amneal Pharmaceuticals, with a $2.45B market cap, has seen a 70% stock return in a year. The company's revenue grew 12.3% in the last year, reaching $2.68B, and is expected to grow 15% in 2024. Key growth strategies include the CREXONT launch, biosimilar pipeline expansion, and new inhalation therapies. Analysts project EPS of $0.63-$0.65 for FY1 and $0.76-$0.87 for FY2, with a positive outlook for sustained growth.
globenewswire.com
·

Parkinson's Disease Market is Expected to Showcase a

Parkinson's disease market to grow at 5.8% CAGR (2020-2034) due to advancements in diagnostics, increased awareness, and a rising number of cases. Emerging therapies like Supernus/Britannia's SPN-830, AbbVie's tavapadon, and Pharma Two B's P2B001 could significantly impact market dynamics. DelveInsight's report covers current treatment practices, emerging drugs, market share, and forecasted market size (2020-2034) for 7MM.
biospace.com
·

7 Most Promising Drugs in Parkinson's Disease Treatment Pipeline

The Parkinson's disease market is expected to grow significantly, reaching USD 6.2 billion by 2034, driven by advancements in diagnostics, disease awareness, and emerging therapies. Key therapies in development include ND0612, tavapadon, P2B001, BIIB122/DNL151, Buntanetap, Solengepras, and Minzasolmin. These therapies aim to improve motor function, manage symptoms, and potentially slow disease progression.
parkinsonsnewstoday.com
·

Despite having early-onset Parkinson's disease, I'm thankful

Diagnosed with Parkinson’s at 36, the author reflects on the impact of clinical trials, reliance on Sinemet, and the importance of a supportive medical team and friends. Despite challenges, the author finds gratitude in small conveniences and the shared perseverance among Parkinson’s patients.
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy